
    
      This is an open-label, Phase II comparative study of an intravitreal dexamethasone implant
      versus intravitreal bevacizumab (Avastin) in 20 patients with recalcitrant diabetic macular
      edema and prior treatment with â‰¥ 2 intravitreal anti-VEGF injections.
    
  